Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (3)

2007

  1. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

    Prostate Cancer and Prostatic Diseases, Vol. 10, Núm. 1, pp. 87-93

2005

  1. Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme

    Prostate Cancer and Prostatic Diseases, Vol. 8, Núm. 2, pp. 194-200

2001

  1. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

    Urology, Vol. 58, Núm. 2, pp. 146-150